Literature DB >> 22788713

Diagnosis and interventions for central serous chorioretinopathy: review and update.

Godfrey Quin1, Gerald Liew, I-Van Ho, Mark Gillies, Samantha Fraser-Bell.   

Abstract

Most acute cases of central serous chorioretinopathy resolve spontaneously with minimal visual impairment. The small percentage of eyes developing chronic or recurrent disease that do warrant treatment is often difficult to control. Emergent investigations and treatments have added to the established options available to manage these cases. Optical coherence tomography has proved valuable for both imaging subtle fundoscopic findings and monitoring disease progression. Fluorescein angiography aids identification of pigment epithelial leaks and targets the use of argon laser treatment if outside the fovea. Fluorescein angiography also assists differentiation from other choroidal pathologies such as choroidal neovascularization and polypoidal choroidal vasculopathy. Where the diagnosis is uncertain, indocyanine green angiography can demonstrate classic midphase hyperpermeability. This is also useful to guide the application of photodynamic therapy. Newer treatments such as intravitreal anti-vascular endothelial growth factor are as yet unproven.
© 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22788713     DOI: 10.1111/j.1442-9071.2012.02847.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  27 in total

1.  Oral eplerenone for the management of chronic central serous chorioretinopathy.

Authors:  Rishi P Singh; Jonathan E Sears; Rumneek Bedi; Andrew P Schachat; Justis P Ehlers; Peter K Kaiser
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

2.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

3.  Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.

Authors:  Dandan Linghu; Hui Xu; Zhiqiao Liang; Tingting Gao; Zhaojun Lin; Xiaoxin Li; Lvzhen Huang; Mingwei Zhao
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

Review 4.  Recent Advances of Organic Near-Infrared II Fluorophores in Optical Properties and Imaging Functions.

Authors:  Haoli Yu; Min Ji
Journal:  Mol Imaging Biol       Date:  2020-10-08       Impact factor: 3.488

5.  QT interval dispersion in the patients with central serous chorioretinopathy.

Authors:  Necati Dagli; Burak Turgut; Rumeysa Tanyildizi; Sabiha Kobat; Mehmet Ali Kobat; Orhan Dogdu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

6.  Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study.

Authors:  Riccardo Sacconi; Livia Tomasso; Eleonora Corbelli; Adriano Carnevali; Lea Querques; Stefano Casati; Francesco Bandello; Giuseppe Querques
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

7.  Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.

Authors:  Francesco Pichi; Paola Carrai; Antonio Ciardella; Francine Behar-Cohen; Paolo Nucci
Journal:  Int Ophthalmol       Date:  2016-10-18       Impact factor: 2.031

8.  Correlation between outer retinal layer thickness and cone density in patients with resolved central serous chorioretinopathy.

Authors:  Tomoko Nakamura; Tomoko Ueda-Consolvo; Toshihiko Oiwake; Atsushi Hayashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-02       Impact factor: 3.117

9.  CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Alexandre Matet; Suzanne Yzer; Emily Y Chew; Alejandra Daruich; Francine Behar-Cohen; Richard F Spaide
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

Review 10.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.